Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Schizophrenic Patients in Integrated Care (CARE II)

This study has been terminated.
(Difficulty finding eligible sites/patients; current situation in health policy cause negative effect on existing/planned contracts for integrated care program)
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00681629
First received: May 20, 2008
Last updated: June 22, 2012
Last verified: June 2012
  Purpose

The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a period of 18 month


Condition Intervention Phase
Schizophrenia
Schizoaffective Disorder
Schizophreniform Disorder
Drug: Quetiapine XR
Other: Integrated Care Program (ICP)
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: CARE II - Evaluation of Treatment Outcomes in Schizophrenic Patients Taking Part in the Integrated Care Program - a Single-country, Multi-centre Phase IV Study

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Subjective Well-being in Patients Treated for Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Delusional Disorder or Psychotic Disorder Not Otherwise Specified Using the SWN-K (Subjective Well-being Under Neuroleptics) Scale [ Time Frame: 4 months ] [ Designated as safety issue: No ]
    The SWN-K is comprised of 20 questions, each of which is rated using a 6 point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20-120, with higher scores implying higher subjective well-being.


Secondary Outcome Measures:
  • Subjective Well-being Using the SWN-K (Subjective Well-being Under Neuroleptics Scale) Total Score [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The SWN-K is comprised of 20 questions, each of which is rated using a 6 point scale ranging from 1 (not at all) to 6 (very much). Possible scores range from 20-120, with higher scores implying higher subjective well-being.

  • Symptomatic Outcome Using CGI-S (Clinical Global Impression-Schizophrenia) Scale [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    With the CGI-S the rate of the severity of a patient's symptoms (positive, negative, cognitive, depressive and overall) using a scale ranging from 1 (normal, not ill) to 7 (among the most severely ill) is measured - higher scores implying higher severity.

  • Symptomatic Outcome Using the PANSS-8 Scales(Positive and Negative Symptoms) Scale Score [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The schizophrenic symptomatology will be measured by the Positive and Negative Syndrome Scale (PANSS) providing 8 items of which each is rated on a severity scale ranging from 1-7, (1= absent - 7 = extreme severe. higher scores implying higher severity.

  • GAF (Global Assessment of Functioning) Scale Score [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The "GAF" is a numeric rating scale used by clinicians for assessment of the social, occupational, psychological functioning of adult patients. The scale represents a hypothetical continuum of mental health illness providing a descending scoring code from 100 until 0. Higher scores indicate better patient condition and performance.

  • PSP (Personal and Social Performance) Scale Score [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The '(PSP" rating scale (100 until 0) used by clinicians for assessment of 4 main domains of functioning in adult patients acc. (a) socially useful activities including work and study, (b) personal and social relationships, (c) self-care, and (d) disturbing and aggressive behavior. Higher scores indicate better patient condition and performance.

  • EQ-5D (European Quality of Life Questionnaire) Score [ Time Frame: 4 month ] [ Designated as safety issue: No ]

    The EQ-5D questionnaire is a generic measure of health status. It defines health in terms of five dimensions:1 (Mobility); 2 (Self-care); 3 (Usual activity); 4 (Pain/Discomfort); 5 (Anxiety/Depression).

    The minimum possible value is 5 (one point for each dimension) and the maximum possible values is 15 (3 points for each dimension). Each dimension has 3 levels of "severity"- "no problems, "some problems" and "extreme problems". Higher scores indicate more problems.


  • Vocational Occupational Index "VOC" Score [ Time Frame: Up to 18 months (V1 Day 1, V2 Month 1, V3 Month 3, V4 Month 6, V5 Month 12, V6 Month 18) ] [ Designated as safety issue: No ]
    The "VOC" index will assess the following 7 items: 1 fulltime gainful employment, 2 homemaker or student, 3 part-time gainful employment (20 hours per week or less), 4 retired, 5 full or part-time volunteer, 6 on medical or psychiatric leave of absence, 7 unemployed, whether or not expected to work. Results will be descriptively summarized. The VOC index will be completed at each visit. Difference from baseline of the index will be derived at each assessment

  • Assess Quality of Life Levels Using the Q-LES-Q-18 (Quality of Life Enjoyment and Satisfaction) Questionnaire [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Q-LES-Q-18 will allow to generate a general QoL-index which will be used for the analysis and is defined as the average of the single scores for all 18 items. Scoring will be carried out from 1-5 per item (never / rarely / sometimes / frequently / all the time). Results will be descriptively summarized.

  • Assess Quality of Life Levels Using the RSM Scale (Riedel-Spellmann-Musil) Scale [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The '(RSM" is a new 36-item measure validated to assess the "QoL" in different dimensions of schizophrenic patient treated with antipsychotics. It will be rated on a four-point Likert scale (not / rather not / rather yes / yes) by the patient and the investigator. The total score ranges from min. 0 to max. of 108. Higher scores indicate higher "QoL".

  • Assess Patient Engagement to Therapy Using the SES Scale (Service Engagement Scale) [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The 'SES" is a 14-item measure consisting of statements that assess the client specific engagement with services. It will be rated on a four-point Likert scale (not at all / rarely / sometimes / most of the time) by the investigator. The total score ranges from min. 0 to a max. of 42. Higher scores indicate lower engagement.

  • Assess Compliance/Medication Adherence Using the MARS Scale (Medication Adherence Rating Scale) [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The 'Medication Adherence Rating Scale' (MARS) is a reliable and valid self-reporting tool for investigation of the compliance in psychiatric patients also recognizing the complexity of compliance behaviour. 10 questions on medication attitude have to be answered by 'yes' or 'no' (8 times 1= no and Yes = 0 and twice 1= no, Yes =1). Results will be descriptively summarized. Summarized results minimum 0: low medication adherence, maximum 10: high medication adherence.

  • Evaluate the Level of the Patients' (Subjective) Satisfaction Using the CSQ-8 Scale (Client Satisfaction Questionnaire) [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The 'CSQ-8" is a brief, self-administered method to monitor the consumer's satisfaction with services in outpatient psychotherapy, showing high internal consistency. It is identified as a core subset of the general CSQ covering 8 Likert-type items with four response choices where '1' indicates the lowest and '4' the highest degree of satisfaction.

  • Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Total Cost by Number of Days With Hospitalization [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Any hospitalisation days in inpatients units and emergency ward stays will be recorded. At each hospitalisation, the number of days will be computed and at each visit, the cumulative total number of days will be used to calculate total costs. As higher the number of hospitalisation days as higher the costs per patient.

  • Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Total Number of Days the Patient Was Not Able to Work or go to School or Complete Routine Daily Activities [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    The number of lost work days, lost school days or days without completing routine daily activities will be evaluated. With any number of lost workdays or lost school days or without completing routine daily activities, the costs will increase and the productivity will decrease.

  • Assess Health Economy Improvements in Terms of a Reduction in Treatment Costs and Loss of Productivity by Determination of the Need for Any Additional Antipsychotic Medication [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Concomitant psychotropic drugs will be coded (ATC = Drug code) to allow a comparison of the number of drugs used per ATC class and per treatment visit. The drugs used will be listed by keeping their brand name for allowing to translate them into costs.

  • Evaluate Safety and Tolerability by Evaluation of Weight/Waist Circumference [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Measuring of weight and waist circumference in centimeter.

  • Evaluate Safety and Tolerability by Evaluation of Laboratory Tests [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Measuring of: B-Haemoglobin (g/dl), B-Haematocrit(%), B-Erythrocyte count(pl), B-Leucocytes count (nl), B-Platelet count(nl), Complete blood count (nl), B-Leucocytes differential count (%), B-HbA1c(%), S-ALAT (U/l), S-ASAT (U/l), S-GGT (U/l), P-Glucose (fasting)(mh/dl), S-prolactin level (ng/ml), S-Pregnancy test (IU/l), Qualitative analysis of urine with Stix®,Urine pregnancy. Comparing results with standard values.

  • Evaluate Safety and Tolerability by Evaluation of Concomitant Medication [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Listing of all concomitant medication to show the efficacy and safety.

  • Evaluate Safety and Tolerability by Evaluation of the Incidence of Adverse Events [ Time Frame: 4 month ] [ Designated as safety issue: No ]
    Listing of all adverse event or SAE´s to show the safety and tolerability.


Enrollment: 7
Study Start Date: July 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Quetiapine XR Alone
Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
Drug: Quetiapine XR
400-800 mg, oral, bid
Other Name: Seroquel Prolong
Experimental: Quetiapine XR With Integrated Care Program (ICP)
Oral administration as 200 mg and 300 mg tablets allowing flexible dosing in 100 mg steps. Once daily in the evening. On day 1: 300 mg quetiapine XR, on day 2 : 600 mg, from day 3 onwards 400 to 800 mg at the centre-specific investigator´s discretion
Drug: Quetiapine XR
400-800 mg, oral, bid
Other Name: Seroquel Prolong
Other: Integrated Care Program (ICP)
Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with baseline SWN-K <=70
  • Provision of signed informed consent
  • Out-patients with schizophrenia, schizophreniform disorder or schizoaffective disorder, severe postpartum depressive disorders with psychotic symptoms and a minimum HAM-D cut off score of 20 points

Exclusion Criteria:

  • Evidence of a clinical relevant disease, eg renal or hepatic impairment, significant coronary heart disease, hepatitis B or C, AIDS
  • Patients with known cardiovascular disease or other condition predisposing to hypotension or family history of QT prolongation
  • Patients who pose an imminent risk of suicide or danger to self or others
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00681629

Locations
Germany
Research Site
Munchen, Bayern, Germany
Research Site
Oranienburg, Brandenburg, Germany
Research Site
Luneburg, Niedersachsen, Germany
Research Site
Oldenburg, Niedersachsen, Germany
Research Site
Chemnitz, Sachsen, Germany
Research Site
Berlin, Germany
Research Site
Hamburg, Germany
Research Site
Stolberg, Germany
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Martin Lambert, MD Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00681629     History of Changes
Other Study ID Numbers: D1443L00048
Study First Received: May 20, 2008
Results First Received: April 7, 2010
Last Updated: June 22, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AstraZeneca:
Schizophrenia
Integrated Care
Quetiapine

Additional relevant MeSH terms:
Disease
Psychotic Disorders
Schizophrenia
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Quetiapine
Antipsychotic Agents
Central Nervous System Agents
Central Nervous System Depressants
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Therapeutic Uses
Tranquilizing Agents

ClinicalTrials.gov processed this record on November 27, 2014